Top 3 Health Care Stocks That Are Set To Fly In March

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Inspire Medical Systems Inc (NYSE:INSP) On March 5, Stifel analyst Jonathan Block maintained Inspire Medical Systems with a Buy and lowered the price target from $95 to $85. The company's stock fell around 7% over the past five days and has a 52-week low of $53.11. RSI Value: 29.9 INSP Price Action: Shares of Inspire Medical fell 3.1% to close at $54.68 on Thursday. Edge Stock Ratings: 2.15 Momentum score with Value at 81.93. Profound Medical Corp (NASDAQ:PROF) On March 5, Profound Medical reported worse-than-expected fourth-quarter financial results. “We continued to execute well, delivering record revenues, an expanded TULSA-PRO installed base, and a stronger capital sales pipeline again in the fourth quarter — validating our belief that Q3-2025 marked an important inflection point in our business,” said Arun Menawat, Profound’s CEO and Chairman. The company's stock fell around 26% over the past month and has a 52-week low of $3.78. RSI Value: 29.9 PROF Price Action: Shares of Profound Medical fell 5.7% to close at $5.16 on Thursday. Benzinga Pro’s charting tool helped identify the trend in PROF stock. Biomarin Pharmaceutical Inc (NASDAQ:BMRN) On March 11, B of A Securities analyst Geoff Meacham maintained BioMarin Pharmaceutical with a Buy and lowered the price target from $97 to $85. The company's stock fell around 14% over the past month and has a 52-week low of $50.76. RSI Value: 29.9 BMRN Price Action: Shares of Biomarin Pharmaceutical fell 0.7% to close at $55.03 on Thursday. Benzinga Pro’s signals feature notified of a potential breakout in BMRN shares. Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare. Photo via Shutterstock